Test of a prostate cancer light-activated treatment device
Treatments studied
Part of Cancer, Kidney & urinary clinical trials.
This study tests the safety and early effectiveness of the SpectraCure P18 system, which uses light-activated medicine to treat prostate cancer that has come back locally after radiation. It may help some people avoid or delay more invasive treatment, while researchers carefully watch side effects.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You were treated with high-dose-rate brachy radiation for localized prostate cancer, and the cancer came back locally on biopsy.
- You are over 18 years old and your prostate size is under 50 cubic centimeters.
- You are not able to have surgery or curative (attempt-to-cure) radiation anymore.
- Your general health is good enough (ECOG 0 or 1) and you have enough time expected (at least 8 months in Phase 1, 12 months in Phase 2).
- Your blood counts, kidney function, and liver blood tests must meet lab thresholds.
- You must be able and willing to give informed consent and follow study visits.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial uses a special light-activated drug (photodynamic therapy) to treat prostate cancer that is still confined to the prostate. It aims to destroy the cancer while sparing healthy tissue, and may be an option for people with intermediate-risk prostate cancer who have not had other treatments.
This trial tests a new type of PET scan to see how well it finds leftover cancer after you've had focal therapy (treatment to just part of the prostate) for intermediate-risk prostate cancer in the last 9 months.
This trial studies a targeted, high-intensity radiation approach given after prostate removal surgery when prostate cancer seems to be coming back locally. It may help control the disease in the pelvis while avoiding treatment that could cause more side effects.
This trial tests a new radiation technique to better protect erectile function during prostate cancer treatment. It uses advanced imaging to precisely target the tumor while reducing harm to nearby structures.
This trial uses a special scan (PSMA-PET) to find where prostate cancer has returned after surgery. Then doctors give a lower dose of radiation only to that area, which may reduce side effects. It is for men whose PSA level is rising after prostate removal.
This trial tests whether adding targeted radiation guided by a PET scan (along with hormone therapy) can improve outcomes for prostate cancer that has come back after surgery. The PET scan helps doctors look for spots outside the usual radiation area so treatment can be tailored.
Hear when a new Recurrent Prostate Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.